Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
14 nov. 2024 16h05 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
23 oct. 2024 08h00 HE
|
Gain Therapeutics, Inc.
GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for...
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
15 oct. 2024 07h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
09 oct. 2024 08h30 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
07 oct. 2024 07h00 HE
|
Gain Therapeutics, Inc.
GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in...
Gain Therapeutics to Participate at Upcoming Investor Conferences
03 oct. 2024 07h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
30 sept. 2024 07h00 HE
|
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) --...
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
26 sept. 2024 07h00 HE
|
Gain Therapeutics, Inc.
Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson’s Disease Patients Event Will Be Held on Monday, September 30, 2024, at...
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
19 sept. 2024 07h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 07h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...